Tumor markers in lung cancer: does the method of obtaining the cut-off point and reference population influence diagnostic yield?
- 1 August 1999
- journal article
- research article
- Published by Elsevier in Clinical Biochemistry
- Vol. 32 (6) , 467-472
- https://doi.org/10.1016/s0009-9120(99)00045-4
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinomaRespiratory Medicine, 1997
- Biology and Molecular Genetics of Lung CancerSeminars in Respiratory and Critical Care Medicine, 1996
- Clinical applications of serum markers for lung cancerRespiratory Medicine, 1995
- Squamous Cell Carcinoma Antigen (SCC Ag) in the Diagnosis and Prognosis of Lung CancerChest, 1994
- Serum tumour markers in lung cancer: history, biology and clinical applicationsEuropean Respiratory Journal, 1994
- Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancerEuropean Journal Of Cancer, 1994
- Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancerEuropean Journal Of Cancer, 1993
- CYFRA 21-1: A new marker in lung cancerCancer, 1993
- Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screeningCancer, 1993
- Clinical Applications of Serum Tumor MarkersAnnals of Internal Medicine, 1991